Metformin/pioglitazone is used to lower blood sugar levels in type 2 diabetes. It鈥檚 used along with diet and exercise.
Market Analysis and Insights: Global Metformin-Pioglitazone Market
The global Metformin-Pioglitazone market is projected to grow from US$ 144 million in 2024 to US$ 179.1 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period.
The combination of metformin and pioglitazone is commonly used in the treatment of type 2 diabetes mellitus. This combination medication works in different ways to help control blood sugar levels and improve insulin sensitivity. Metformin and pioglitazone have both demonstrated efficacy in managing diabetes. Combining these two medications can provide better glycemic control compared to using either drug alone. The dual mechanism of action helps address the underlying causes of insulin resistance and impaired glucose metabolism, leading to improved outcomes for patients. Metformin and pioglitazone have complementary actions. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while pioglitazone increases peripheral glucose utilization and reduces insulin resistance. This combination maximizes the benefits of each drug and offers a more comprehensive approach to diabetes treatment. The safety profiles of metformin and pioglitazone are well established. Metformin is generally well-tolerated, and pioglitazone has a well-documented safety record. By combining these drugs, physicians can minimize the risk of adverse effects associated with higher doses of a single medication. Diabetes is a complex and chronic condition that often requires a multifaceted treatment approach. The metformin-pioglitazone combination provides comprehensive glycemic control by targeting multiple pathways involved in glucose regulation. This makes it an attractive option for healthcare providers seeking an effective and convenient treatment strategy. With the rising prevalence of type 2 diabetes globally, there is an increasing demand for effective and well-tolerated treatment options. Metformin-pioglitazone combination therapy has gained market acceptance due to its proven efficacy, safety, and convenience.
Report Covers:
This report presents an overview of global market for Metformin-Pioglitazone market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Metformin-Pioglitazone, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Metformin-Pioglitazone, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Metformin-Pioglitazone revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Metformin-Pioglitazone market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Metformin-Pioglitazone revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Takeda Pharmaceuticals
Mylan
Teva
Sandoz
Aurobindo Pharma
MACLEODS
Torrent Pharmaceuticals
Wellona Pharma
BLUE CROSS
Neurocon Inc
Segment by Type
Tablets: 15 mg pioglitazone/1000 mg metformin HCl
Tablets: 30 mg pioglitazone/1000 mg metformin HCl
Segment by Application
Hospital
Drug store
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Metformin-Pioglitazone in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metformin-Pioglitazone companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metformin-Pioglitazone revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metformin-Pioglitazone Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Tablets: 15 mg pioglitazone/1000 mg metformin HCl
1.2.3 Tablets: 30 mg pioglitazone/1000 mg metformin HCl
1.3 Market by Application
1.3.1 Global Metformin-Pioglitazone Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Drug store
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metformin-Pioglitazone Market Perspective (2019-2030)
2.2 Global Metformin-Pioglitazone Growth Trends by Region
2.2.1 Metformin-Pioglitazone Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Metformin-Pioglitazone Historic Market Size by Region (2019-2024)
2.2.3 Metformin-Pioglitazone Forecasted Market Size by Region (2025-2030)
2.3 Metformin-Pioglitazone Market Dynamics
2.3.1 Metformin-Pioglitazone Industry Trends
2.3.2 Metformin-Pioglitazone Market Drivers
2.3.3 Metformin-Pioglitazone Market Challenges
2.3.4 Metformin-Pioglitazone Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Metformin-Pioglitazone by Players
3.1.1 Global Metformin-Pioglitazone Revenue by Players (2019-2024)
3.1.2 Global Metformin-Pioglitazone Revenue Market Share by Players (2019-2024)
3.2 Global Metformin-Pioglitazone Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Metformin-Pioglitazone, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Metformin-Pioglitazone Market Concentration Ratio
3.4.1 Global Metformin-Pioglitazone Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metformin-Pioglitazone Revenue in 2023
3.5 Global Key Players of Metformin-Pioglitazone Head office and Area Served
3.6 Global Key Players of Metformin-Pioglitazone, Product and Application
3.7 Global Key Players of Metformin-Pioglitazone, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Metformin-Pioglitazone Breakdown Data by Type
4.1 Global Metformin-Pioglitazone Historic Market Size by Type (2019-2024)
4.2 Global Metformin-Pioglitazone Forecasted Market Size by Type (2025-2030)
5 Metformin-Pioglitazone Breakdown Data by Application
5.1 Global Metformin-Pioglitazone Historic Market Size by Application (2019-2024)
5.2 Global Metformin-Pioglitazone Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Metformin-Pioglitazone Market Size (2019-2030)
6.2 North America Metformin-Pioglitazone Market Size by Type
6.2.1 North America Metformin-Pioglitazone Market Size by Type (2019-2024)
6.2.2 North America Metformin-Pioglitazone Market Size by Type (2025-2030)
6.2.3 North America Metformin-Pioglitazone Market Share by Type (2019-2030)
6.3 North America Metformin-Pioglitazone Market Size by Application
6.3.1 North America Metformin-Pioglitazone Market Size by Application (2019-2024)
6.3.2 North America Metformin-Pioglitazone Market Size by Application (2025-2030)
6.3.3 North America Metformin-Pioglitazone Market Share by Application (2019-2030)
6.4 North America Metformin-Pioglitazone Market Size by Country
6.4.1 North America Metformin-Pioglitazone Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Metformin-Pioglitazone Market Size by Country (2019-2024)
6.4.3 North America Metformin-Pioglitazone Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Metformin-Pioglitazone Market Size (2019-2030)
7.2 Europe Metformin-Pioglitazone Market Size by Type
7.2.1 Europe Metformin-Pioglitazone Market Size by Type (2019-2024)
7.2.2 Europe Metformin-Pioglitazone Market Size by Type (2025-2030)
7.2.3 Europe Metformin-Pioglitazone Market Share by Type (2019-2030)
7.3 Europe Metformin-Pioglitazone Market Size by Application
7.3.1 Europe Metformin-Pioglitazone Market Size by Application (2019-2024)
7.3.2 Europe Metformin-Pioglitazone Market Size by Application (2025-2030)
7.3.3 Europe Metformin-Pioglitazone Market Share by Application (2019-2030)
7.4 Europe Metformin-Pioglitazone Market Size by Country
7.4.1 Europe Metformin-Pioglitazone Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Metformin-Pioglitazone Market Size by Country (2019-2024)
7.4.3 Europe Metformin-Pioglitazone Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Metformin-Pioglitazone Market Size (2019-2030)
8.2 China Metformin-Pioglitazone Market Size by Type
8.2.1 China Metformin-Pioglitazone Market Size by Type (2019-2024)
8.2.2 China Metformin-Pioglitazone Market Size by Type (2025-2030)
8.2.3 China Metformin-Pioglitazone Market Share by Type (2019-2030)
8.3 China Metformin-Pioglitazone Market Size by Application
8.3.1 China Metformin-Pioglitazone Market Size by Application (2019-2024)
8.3.2 China Metformin-Pioglitazone Market Size by Application (2025-2030)
8.3.3 China Metformin-Pioglitazone Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Metformin-Pioglitazone Market Size (2019-2030)
9.2 Asia Metformin-Pioglitazone Market Size by Type
9.2.1 Asia Metformin-Pioglitazone Market Size by Type (2019-2024)
9.2.2 Asia Metformin-Pioglitazone Market Size by Type (2025-2030)
9.2.3 Asia Metformin-Pioglitazone Market Share by Type (2019-2030)
9.3 Asia Metformin-Pioglitazone Market Size by Application
9.3.1 Asia Metformin-Pioglitazone Market Size by Application (2019-2024)
9.3.2 Asia Metformin-Pioglitazone Market Size by Application (2025-2030)
9.3.3 Asia Metformin-Pioglitazone Market Share by Application (2019-2030)
9.4 Asia Metformin-Pioglitazone Market Size by Region
9.4.1 Asia Metformin-Pioglitazone Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Metformin-Pioglitazone Market Size by Region (2019-2024)
9.4.3 Asia Metformin-Pioglitazone Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Type
10.2.1 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Application
10.3.1 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Country
10.4.1 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Metformin-Pioglitazone Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Company Details
11.1.2 Takeda Pharmaceuticals Business Overview
11.1.3 Takeda Pharmaceuticals Metformin-Pioglitazone Introduction
11.1.4 Takeda Pharmaceuticals Revenue in Metformin-Pioglitazone Business (2019-2024)
11.1.5 Takeda Pharmaceuticals Recent Developments
11.2 Mylan
11.2.1 Mylan Company Details
11.2.2 Mylan Business Overview
11.2.3 Mylan Metformin-Pioglitazone Introduction
11.2.4 Mylan Revenue in Metformin-Pioglitazone Business (2019-2024)
11.2.5 Mylan Recent Developments
11.3 Teva
11.3.1 Teva Company Details
11.3.2 Teva Business Overview
11.3.3 Teva Metformin-Pioglitazone Introduction
11.3.4 Teva Revenue in Metformin-Pioglitazone Business (2019-2024)
11.3.5 Teva Recent Developments
11.4 Sandoz
11.4.1 Sandoz Company Details
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Metformin-Pioglitazone Introduction
11.4.4 Sandoz Revenue in Metformin-Pioglitazone Business (2019-2024)
11.4.5 Sandoz Recent Developments
11.5 Aurobindo Pharma
11.5.1 Aurobindo Pharma Company Details
11.5.2 Aurobindo Pharma Business Overview
11.5.3 Aurobindo Pharma Metformin-Pioglitazone Introduction
11.5.4 Aurobindo Pharma Revenue in Metformin-Pioglitazone Business (2019-2024)
11.5.5 Aurobindo Pharma Recent Developments
11.6 MACLEODS
11.6.1 MACLEODS Company Details
11.6.2 MACLEODS Business Overview
11.6.3 MACLEODS Metformin-Pioglitazone Introduction
11.6.4 MACLEODS Revenue in Metformin-Pioglitazone Business (2019-2024)
11.6.5 MACLEODS Recent Developments
11.7 Torrent Pharmaceuticals
11.7.1 Torrent Pharmaceuticals Company Details
11.7.2 Torrent Pharmaceuticals Business Overview
11.7.3 Torrent Pharmaceuticals Metformin-Pioglitazone Introduction
11.7.4 Torrent Pharmaceuticals Revenue in Metformin-Pioglitazone Business (2019-2024)
11.7.5 Torrent Pharmaceuticals Recent Developments
11.8 Wellona Pharma
11.8.1 Wellona Pharma Company Details
11.8.2 Wellona Pharma Business Overview
11.8.3 Wellona Pharma Metformin-Pioglitazone Introduction
11.8.4 Wellona Pharma Revenue in Metformin-Pioglitazone Business (2019-2024)
11.8.5 Wellona Pharma Recent Developments
11.9 BLUE CROSS
11.9.1 BLUE CROSS Company Details
11.9.2 BLUE CROSS Business Overview
11.9.3 BLUE CROSS Metformin-Pioglitazone Introduction
11.9.4 BLUE CROSS Revenue in Metformin-Pioglitazone Business (2019-2024)
11.9.5 BLUE CROSS Recent Developments
11.10 Neurocon Inc
11.10.1 Neurocon Inc Company Details
11.10.2 Neurocon Inc Business Overview
11.10.3 Neurocon Inc Metformin-Pioglitazone Introduction
11.10.4 Neurocon Inc Revenue in Metformin-Pioglitazone Business (2019-2024)
11.10.5 Neurocon Inc Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Takeda Pharmaceuticals
Mylan
Teva
Sandoz
Aurobindo Pharma
MACLEODS
Torrent Pharmaceuticals
Wellona Pharma
BLUE CROSS
Neurocon Inc
听
听
*If Applicable.